The ecological fitness of the tomato potato psyllid after transferring from non-crop host plants to tomato and potato.

An insect's fitness varies on different host plant species, and can be affected by previous host feeding experience. In New Zealand, Bactericera cockerelli (the tomato potato psyllid (TPP)) overwinter on various host species, and later migrate to annually grown crop host plants. How changing host plant species affects the insect's fitness is unknown. This study evaluated if transferring adult TPP from non-crop to crop host species impacts the development and survival of their progeny. TPP were reared on non-crop host species, boxthorn, poroporo, and crop host species, potato and tomato. Adults were transferred from non-crop to the crop host species and allowed to oviposit for 48 hours before being removed. The eggs and nymphs were monitored every 24 hours for the development and survival of each life stage. The incubation period of eggs from adults transferred from poroporo to tomato was 6.9 days, and for boxthorn to tomato was 7.2 days, and was less than for eggs of adults moved from tomato to tomato (9.0 days) and potato to potato (9.2 days) (P < 0.05). Nymph developmental time was similar for all treatments. Total development time (egg to adult) was shorter for the progeny of adults from poroporo transferred to tomato (20.5 days) than those from tomato to tomato (23.2). The survival of eggs did not differ across treatments. Fewer nymphs survived when adults were transferred from tomato to tomato (50.4%) than those from poroporo to tomato (92.1%) (P < 0.05). Total survival (egg to adult) was higher for progeny of adults transferred from poroporo to tomato (80.0%) compared to boxthorn to potato (35.3%), boxthorn to boxthorn (40.7%), poroporo to potato (33.9%) and tomato to tomato (37.6%) (P < 0.05). The implications of this shift in fitness are discussed in relation to TPP management.

Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost.

PURPOSE: Guidelines from the American Society of Clinical Oncology and Cancer Care Ontario recommend brachytherapy boost for patients with intermediate-risk or high-risk prostate cancer. SABR is an emerging technique for prostate cancer, but its use in high-risk disease is limited. Efficacy, toxic effects, and quality of life (QoL) were compared in patients treated on 2 prospective protocols that used SABR boost or magnetic resonance-guided high-dose-rate brachytherapy (HDR-BT) boost with 6 to 18 months of androgen deprivation therapy (ADT). METHODS AND MATERIALS: In SATURN study (study 1), patients received 40 Gy to the prostate and 25 Gy to the pelvis in 5 weekly fractions. In SPARE (study 2), patients received HDR-BT (15 Gy × 1) to the prostate and ≤22.5 Gy to the magnetic resonance imaging nodule, followed by 25 Gy in 5 weekly fractions to the pelvis. All patients received between 6 and 18 months of ADT. RESULTS: Thirty patients (7% unfavorable intermediate risk and 93% high risk, per National Comprehensive Cancer Network [NCCN] criteria) completed study 1, and 31 patients (3% favorable intermediate risk, 47% unfavorable intermediate risk, and 50% high risk) completed treatment as per study 2. The median follow-up times were 72 and 62 months, respectively. In study 2, 6 patients had biochemical failure, and all 6 developed metastatic disease. Actuarial 5-year biochemical failure was 0% for study 1 and 18.2% for study 2 (P = .005). There was no significant difference in the worst acute or late gastrointestinal or genitourinary toxicity. Grade 3 late genitourinary toxicity was noted in 3% of the patients in study 2 (HDR-BT boost). There was either no significant difference or minimal clinically important change in QoL. CONCLUSIONS: In the context of 5-fraction pelvic radiation therapy and ADT, there did not appear to be a significant difference in toxicity or QoL between SABR and HDR-BT boost. Although efficacy favored the SABR boost cohort, this should be viewed in the context of limitations and biases associated with comparing 2 sequential phase 2 studies.

Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

PURPOSE: This study identified predictors of high-grade late hematochezia (HH) following 5-fraction gantry-based stereotactic ablative radiation therapy (SABR). METHODS AND MATERIALS: Hematochezia data for 258 patients who received 35 to 40 Gy SABR in 5-fractions as part of sequential phase 2 prospective trials was retrieved. Grade 2 or higher late rectal bleeding was labeled HH. Hematochezia needing steroid suppositories, 4% formalin, or 1 to 2 sessions of argon plasma coagulation (APC) was labeled grade 2. More than 2 sessions of APC, blood transfusion, or a course of hyperbaric oxygen was grade 3 and development of visceral fistula, grade 4. Various dosimetric and clinical factors were analyzed using univariate and multivariate analyses. Receiver operating characteristic (ROC) curve analysis and recursive partitioning analysis were used to determine clinically valid cut-off points and identify risk groups, respectively. RESULTS: HH was observed in 19.4%, grade ≥3 toxicity in 3.1%. Median follow-up was 29.7 months (interquartile range [IQR]: 20.6-61.7) Median time to develop HH was 11.7 months (IQR: 9.0-15.2) from the start of radiation. At 2 years, cumulative HH was 4.9%, 27.2%, and 42.1% in patients who received 35 Gy to prostate (4-mm planning target volume [PTV] margin), 40 Gy to prostate (5-mm PTV margin), and 40 Gy to prostate/seminal vesicles (5-mm PTV margin), respectively (P<.0001). In the ROC analysis, volume of rectum receiving radiation dose of 38 Gy (V38) was a strong predictor of HH with an area under the curve of 0.65. In multivariate analysis, rectal V38 (≥2.0 cm(3); odds ratio [OR]: 4.7); use of anticoagulants in the follow-up period (OR: 6.5) and presence of hemorrhoids (OR: 2.7) were the strongest predictors. Recursive partitioning analysis showed rectal V38 < 2.0 cm(3), and use of anticoagulants or rectal V38 ≥ 2.0 cm(3) plus 1 other risk factor resulted in an HH risk of >30%. CONCLUSIONS: Rectal V38 and 2 clinical factors were strong predictors of HH following 5-fraction SABR. Planning constraints should keep rectal V38 below 2.0 cm(3).

Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix.

INTRODUCTION: A regimen of concurrent chemoradiation for definitive treatment of cervical cancer is widely used. This retrospective review has been conducted to determine the outcomes and late toxic effect associated with the specific regimen of whole-pelvic external beam radiotherapy of 45 Gy in 25 fractions with parametrial boosts of 5.4 or 9 Gy and HDR brachytherapy (BT) of 30 Gy in 5 fractions to point A delivered by tandem and ring. This protocol is accepted by the Gynecological Oncology Group and endorsed by the American Brachytherapy Society, but no late toxic effect data have been reported. MATERIALS AND METHODS: The electronic records of sequential patients treated definitively at the Sunnybrook Odette Cancer Centre between January 2006 and December 2008 were reviewed. Patient-, tumor-, and treatment-related details (including external beam radiotherapy, BT, and chemotherapy) were obtained. Outcome measures included disease-free status, dates and sites of first recurrence, survival, and grade 3/4 late toxic effect results (Common Terminology Criteria Adverse Events 3.0 criteria). Exclusion criteria were no follow-up or a planned alternative regimen. RESULTS: One hundred twenty-two patients (+11 excluded) were treated with a median follow-up of 18 months from diagnosis. The actuarial 2-year disease-free survival rate was 70%. The median time to recurrence was 8 months (range, 2-22 months). The median time to toxic effect was 10 months (range 4-27 months). Grade 3/4 toxic effect was observed in 13 patients (11%). The actuarial grade 3/4 toxic effect rate at 2 years was 14%. CONCLUSIONS: Despite a relatively short follow-up, the toxicity of this regimen seems high compared with other retrospective series, although pelvic control is good. Consideration should be given to a reduction in BT dose alternatively when feasible image-guided BT may allow maintenance of tumor dose with reduced dose to organs at risk.

4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments.

On the basis of structural and/or aroma analogies to known thrips (Thysanoptera: Thripidae) lures, 35 compounds (18 pyridine derivatives, 13 benzene derivatives, and 4 other compounds), consisting of both synthetic and naturally occurring compounds, were screened for their ability to bring about increased thrips capture in field experiments using water traps in Canterbury, New Zealand. Most of the thrips caught were New Zealand flower thrips (NZFT) (Thrips obscuratus) or onion thrips (OT) (Thrips tabaci). The greatest increase in capture for NZFT (158 times for female symbol cf. to water control) was for the known lure ethyl nicotinate, a 3-pyridyl ester. Ethyl isonicotinate, the 4-pyridyl regioisomer of ethyl nicotinate, not previously reported as a thrips lure, provided the greatest increases in capture for OT (31 times) of any of the compounds tested, significantly more than ethyl nicotinate. Other 4-pyridyl carbonyl compounds, including ethyl 4-pyridyl ketone, also increased OT capture significantly. The natural floral compound cis-jasmone, which increased trap capture of NZFT (female symbol 42 times, male symbol 25 times) but not OT, is reported as a thrips lure for the first time.